Teacher Retirement System of Texas Has $6.32 Million Position in Becton, Dickinson and Company $BDX

Key Points

• Teacher Retirement System of Texas trimmed its Becton, Dickinson & Company stake by 22.6% in Q4 to 32,580 shares, worth about $6.32 million.
• Becton, Dickinson reported Q earnings of $2.91 EPS (beat), revenue of $4.49B (miss), set FY2026 guidance of $12.35–12.65 EPS, and carries a consensus analyst rating of "Hold" with a $189.08 target.
• The company pays a quarterly dividend of $1.05 (annualized $4.20, ~2.8% yield) and its board approved a $10 million share repurchase program.

Teacher Retirement System of Texas reduced its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,580 shares of the medical instruments supplier's stock after selling 9,517 shares during the period. Teacher Retirement System of Texas' holdings in Becton, Dickinson and Company were worth $6,323,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Activest Wealth Management increased its stake in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. SOA Wealth Advisors LLC. grew its position in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 95 shares during the period. Steph & Co. grew its position in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 65 shares during the period. Finally, Accredited Wealth Management LLC grew its position in shares of Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 70 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a research report on Tuesday, February 10th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Friday, April 10th. They issued a "neutral" rating and a $167.00 price objective for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $189.08.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $152.15 on Monday. The company has a market capitalization of $43.32 billion, a price-to-earnings ratio of 24.82, a PEG ratio of 10.82 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a 50-day simple moving average of $163.18 and a 200 day simple moving average of $183.02. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company's revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company's payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its stock is undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company's stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.40% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.